Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics Reports Third Quarter 2016 Operational Highlights and Financial Results

PR Newswire November 1, 2016

Synthetic Biologics to Report Third Quarter 2016 Operational Highlights and Financial Results on November 1, 2016

PR Newswire October 25, 2016

Synthetic Biologics Awarded Research Contract from Centers for Disease Control and Prevention (CDC) for Microbiome Assessment and Intervention to Address Antibiotic Resistance

PR Newswire October 6, 2016

Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire May 23, 2016

Synthetic Biologics to Host Post-DDW 2016® Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire May 17, 2016

Synthetic Biologics Announces Positive Topline Results from Second Phase 2a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea

PR Newswire May 16, 2016

Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development

PR Newswire May 11, 2016

Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs

PR Newswire May 9, 2016

Synthetic Biologics Reports First Quarter 2016 Operational Highlights and Financial Results

PR Newswire May 5, 2016

Synthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results

PR Newswire March 10, 2016

Synthetic Biologics to Present at the 28th Annual ROTH Conference

PR Newswire March 9, 2016

Synthetic Biologics to Report 2015 Year End Results on March 10, 2016

PR Newswire March 3, 2016

Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea

PR Newswire March 1, 2016

Synthetic Biologics Reports Allowance Of Key U.S. Patent Covering SYN-010 For Novel Treatment Of IBS-C

Press Releases February 17, 2016

Astronics Sees FY Revenue $665M to $725M vs $726M est

Press Releases February 17, 2016

Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

Press Releases February 17, 2016

Synthetic Biologics to Participate in Fireside Chat at RBC Capital Markets' Global Healthcare Conference

Press Releases February 16, 2016

Synthetic Biologics to Present at the 2016 BIO CEO & Investor Conference

PR Newswire February 3, 2016

Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta(TM) Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis

PR Newswire February 2, 2016

Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire January 19, 2016